Navigation Links
Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial
Date:12/2/2009

innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara®. Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the risk that that the results of future clinical studies will not correlate or be consistent with the results of the completed studies to date and the risk that the company will experience delays or difficulties in enrolling patients in any planned future clinical studies. Factors that could cause actual results to differ materially or otherwise adversely impact the company's ability to obtain regulatory approval for its product candidates include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are current
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... 2015 Research and ... addition of the "Oxidative Stress Assay ... Type (Indirect, Enzyme-based, Reactive Oxygen Species (ROS)-based), ... - Global Forecast to 2020" report ... http://photos.prnewswire.com/prnh/20130307/600769) , The global oxidative ...
(Date:6/1/2015)... 2015 GenomeDx Biosciences today announced ... successfully classified various subtypes of bladder cancer ... biomarkers, including one type associated with resistance ... signature has potential as a tool to ... patients with muscle-invasive bladder cancers (MIBC). The ...
(Date:6/1/2015)... , June 1, 2015  Novartis is ... study of CTL019, an investigational chimeric antigen receptor ... in the treatment of specific types of hard-to-treat ... by the University of Pennsylvania,s Perelman School of ... (r/r) diffuse large B-cell lymphoma (DLBCL) and follicular ...
(Date:6/1/2015)... June 01, 2015 Regis Technologies, ... manufacturing of chiral stationary phases (CSPs) for analytical ... its current and presenting solutions for new clients, ... portfolio. This valuable addition to its core expertise ... advantage that can tackle projects for the scale ...
Breaking Biology Technology:Oxidative Stress Assay Market 2015 - Global Forecast to 2020 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6Regis Technologies Offers Chiral Chromatography Service 2Regis Technologies Offers Chiral Chromatography Service 3
... , Baltimore Convention Center ... BALTIMORE, Aug. 11 This summit will attract more than 1,200 ... It will feature more than 100 speakers, including governors, federal officials, ... cell policies, scientific breakthroughs, and human-interest stories. This is your ...
... , SAN FRANCISCO, Aug. 11 ... stage biopharmaceutical company developing a proprietary breakthrough class of targeted ... private placement financing with gross proceeds of US $5,123,521, exceeding ... anticipated on or before September 15, 2009, with additional proceeds ...
... 11 /PRNewswire-Asia-FirstCall/ -- American Oriental,Bioengineering, Inc. (NYSE: ... to improving health through the development, manufacture and,commercialization of ... ("OTC"),products in China, announced today that the Audit Committee ... of Ernst & Young Hua Ming ("EY") as,the Company,s ...
Cached Biology Technology:World Stem Cell Summit to Be Held in Baltimore 2Jennerex Closes $5 Million First Tranche of Series C Financing 2
(Date:6/1/2015)... According to a new market research report ... & Touchless), Application (Consumer Electronics, Automotive, & Others), Product ... Forecast to 2020", published by MarketsandMarkets, the Gesture Recognition ... Billion by 2020, at a CAGR of 28.23% between ... data T ables and   86   F ...
(Date:6/1/2015)... , June 1, 2015 ... "Next Generation Biometrics Market by Application (Government, Military ... Travel & Immigration, and Security), Technology (Face Recognition, ... Signature Recognition, Vein Recognition, and Others), Function (Contact ... , Europe , APAC, ...
(Date:5/29/2015)... DUBLIN , May 28, 2015 ... the addition of the "Facial Recognition Market ... User - Global Forecast to 2020" report ... years, have seen facial recognition technology become more ... technology to gain traction and investment from the ...
Breaking Biology News(10 mins):Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 2Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 3Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 4Next Generation Biometrics Market Worth $24,448.84 Million by 2020 2Next Generation Biometrics Market Worth $24,448.84 Million by 2020 3Next Generation Biometrics Market Worth $24,448.84 Million by 2020 4Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2
... Two proteins interact in a previously unknown molecular mechanism ... for the causes of defective organs in fetuses, metastatic ... Children,s Hospital Medical Center. Reporting their work in ... researchers said the mechanism coordinates cell identity and behavior ...
... shells to bones, the skeletons of organisms contain small ... levels of these elements provide important clues to past ... to relate impurity contents to the ancient environments in ... 31 issue of Science magazine, Allison Stephenson, ...
... have unlocked part of the mystery underlying a childhood eye disease. ... end up with missing or extra pieces of DNA. The ... (CNVs). The U of A research team had previously shown how ... glaucoma a disease that can lead to blindness. In their ...
Cached Biology News:New regulatory mechanism discovered for cell identify and behavior in forming organs 2New regulatory mechanism discovered for cell identify and behavior in forming organs 3Bare bones of crystal growth: Biomolecules enhance metal contents in calcite 2
DDO Immunogen: DDO (NP_003640, 270 a.a. ~ 370 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Goat polyclonal to T7 tag (Agarose) Immunogen: Goats were immunized with MASMTGGQQMG (T7) conjugated to KLH.After multiple immunizations in Freund's adjuvant, serum was collected....
... WinList come straight from the folks who ... automatic region positioning, N-Stat regions, and presentation-quality ... thoughtful conversations, and careful design. Of course, ... are still there, too. WinList leads the ...
C/EBPdelta Antibody Shipping Temperature: Cold Storage Temperature: -20C...
Biology Products: